Suven Life Sciences slumped 8.56% to Rs 98.30 after the company reported a consolidated net loss of Rs 21.69 crore in Q4 FY21 compared with net loss of Rs 25.74 crore in Q4 FY20.
Total income during the quarter tumbled 75.3% year-on-year to Rs 2.88 crore. R&D and operational expense declined 31.4% to Rs 23.13 crore in Q4 FY21 over Q4 FY20.
On a consolidated basis, the company reported a net loss of Rs 72.45 crore in the year ended 31 March 2021 compared with net loss of Rs 94.51 crore the year ended 31 March 2020. Total income fell 25.4% to Rs 21.23 crore in FY21 over FY20.
Suven Life Sciences, a biopharmaceutical company, engaged in drug discovery and development of new chemical entities (NCEs) in central nervous system (CNS) disorders targeting unmet medical needs, globally.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU